Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

被引：0
|
作者：
Kaklamani, Virginia G.
Bardia, Aditya
Aftimos, Philippe Georges
Cortes, Javier
Lu, Janice M.
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joohyuk
Taylor, Donatienne
Harnden, Kathleen Kiernan
Khong, Hung T.
Kocsis, Judit
Dalenc, Florence
Dillon, Patrick Michael
Tonini, Giulia
Grzegorzewski, Kris
Bidard, Francois-Clement
机构：
[1] Univ Texas Hlth Sci Ctr, Houston, TX USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[4] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain
[5] Univ Europea Madrid, Madrid, Spain
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Univ Ziekenhuizen UZ, Leuven Canc Inst, Leuven, Belgium
[8] Ctr Med Austral, Buenos Aires, Argentina
[9] Case Western Reserve Univ, Cleveland, OH USA
[10] Seidman Canc Ctr, UH, Cleveland, OH USA
[11] Ctr Hosp Ardenne, Site Libramont, Libramont, Belgium
[12] Ctr Jean Perrin, Clermont Ferrand, France
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Univ Catholic Louvain, CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium
[15] Inova Schar Canc Ctr, Fairfax, VA USA
[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[17] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary
[18] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[19] Univ Virginia Hlth Syst, Charlottesville, VA USA
[20] Menarini Grp, Florence, Italy
[21] Menarini Grp, Stemline Therapeut, New York, NY USA
[22] Inst Curie, Paris, France
[23] Inst Curie, St Cloud, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1100
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
    De Vries, Elisabeth
    Venema, Clasina Marieke
    Glaudemans, Andor W. J. M.
    Fitzpatrick, Lorraine
    Purandare, Dinesh
    Hattersley, Gary
    Garner, Fiona
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
    Tamura, Kenji
    Mukohara, Toru
    Yonemori, Kan
    Kawabata, Yumiko
    Nicolas, Xavier
    Tanaka, Tomoyuki
    Iwata, Hiroji
    BREAST CANCER, 2023, 30 (03) : 506 - 517
  • [43] Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
    Kenji Tamura
    Toru Mukohara
    Kan Yonemori
    Yumiko Kawabata
    Xavier Nicolas
    Tomoyuki Tanaka
    Hiroji Iwata
    Breast Cancer, 2023, 30 : 506 - 517
  • [44] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [45] A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
    Linden, Hannah M.
    Campone, Mario
    Bardia, Aditya
    Ulaner, Gary A.
    Gosselin, Alice
    Doroumian, Severine
    Pelekanou, Vasiliki
    Celanovic, Marina
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2021, 81 (04)
  • [46] AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER plus / human epidermal growth factor receptor 2-negative (HER-2) metastatic breast cancer (mBC).
    Chandarlapaty, Sarat
    Linden, Hannah M.
    Neven, Patrick
    Petrakova, Katarina
    Bardia, Aditya
    Kabos, Peter
    Braga, Sofia A. D. S.
    Boni, Valentina
    Gosselin, Alice
    Cartot-Cotton, Sylvaine
    Doroumian, Severine
    Celanovic, Marina
    Cohen, Patrick
    Paux, Gautier
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER plus ) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
    Jhaveri, Komal L.
    Jeselsohn, Rinath
    Lim, Elgene
    Hamilton, Erika P.
    Yonemori, Kan
    Beck, J. Thaddeus
    Kaufman, Peter A.
    Sammons, Sarah
    Bhave, Manali A.
    Saura, Cristina
    Calvo, Emiliano
    Meniawy, Tarek
    Larson, Timothy
    Ma, Cynthia X.
    Garcia-Corbacho, Javier
    Cao, Shanshan
    Estrem, Shawn T.
    Milata, Jennifer L.
    Nguyen, Bastien
    Beeram, Muralidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Tolaney, Sara M.
    Chan, Arlene
    Petrakova, Katarina
    Delaloge, Suzette
    Campone, Mario
    Iwata, Hiroji
    Peddi, Parvin F.
    Kaufman, Peter A.
    De Kermadec, Elisabeth
    Liu, Qianying
    Cohen, Patrick
    Paux, Gautier
    Wang, Lei
    Ternes, Nils
    Boitier, Eric
    Im, Seock-Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (24) : 4014 - +
  • [49] A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER-positive, HER2-negative, postmenopausal advanced breast cancer patients.
    Harb, Wael A.
    Garner, Fiona
    Clarkin, Marcie
    Roberge, Kathleen A.
    Harris, Alan G.
    Williams, Gregory
    Hattersley, Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
    Martin Jimenez, M.
    Lim, E.
    Mac Gregor, M. Chavez
    Bardia, A.
    Wu, J.
    Zhang, Q.
    Nowecki, Z.
    Cruz, F.
    Safin, R.
    Kim, S-B.
    Schem, C.
    Montero, A.
    Khan, S.
    Bandyopadhyay, R.
    Shivhare, M.
    Patre, M.
    Martinalbo, J.
    Roncoroni, L.
    Perez-Moreno, P. D.
    Sohn, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S633 - S634
12345